{
 "checked": "2026-10-25",
 "page": "https://jabbitapp.com/research/slu-pp-332-exercise-pill-err-agonist-evidence-teardown.html",
 "compound": {
  "name": "SLU-PP-332",
  "pubchem_cid": 5338394,
  "formula": "C18H14N2O2",
  "mw": "290.3",
  "iupac": "4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide",
  "class": "small molecule (acyl hydrazone), not a peptide"
 },
 "pubmed": {
  "query": "\"slu pp 332\"[All Fields] OR \"slu pp 332\"[All Fields] OR \"SLU-PP-915\"[All Fields]",
  "count": 12,
  "human_trials_found": 0
 },
 "abstract_quotes": {
  "36988910": {
   "title": "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity",
   "journal": "ACS Chem Biol",
   "year": "2023",
   "quotes": [
    "we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα.",
    "When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise endurance."
   ]
  },
  "37739806": {
   "title": "A Synthetic ERR Agonist Alleviates Metabolic Syndrome",
   "journal": "J Pharmacol Exp Ther",
   "year": "2024",
   "quotes": [
    "Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome.",
    "These effects were accompanied by decreased fat mass accumulation.",
    "the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome."
   ]
  },
  "37961903": {
   "title": "Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function",
   "journal": "Circulation",
   "year": "2024",
   "quotes": [
    "Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced HF without affecting cardiac hypertrophy.",
    "compounds with pharmacokinetics appropriate for in vivo use have not been available"
   ]
  },
  "37717940": {
   "title": "Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney",
   "journal": "Am J Pathol",
   "year": "2023",
   "quotes": [
    "The ERRs were decreased in both aging human and mouse kidneys",
    "A pan-ERR agonist, SLU-PP-332, was used to treat 21-month-old mice for 8 weeks.",
    "reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines"
   ]
  },
  "37421886": {
   "title": "Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915",
   "journal": "Eur J Med Chem",
   "year": "2023",
   "quotes": [
    "One potent agonist, SLU-PP-915 (10s)"
   ]
  },
  "40692696": {
   "title": "Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study",
   "journal": "Front Physiol",
   "year": "2025",
   "quotes": [
    "Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled",
    "Primary cultures of myoblasts were set up from the muscle tissue of inactive women and treated with the ERRs agonist, SLU-PP-332",
    "Targeting ERRs could represent a promising therapeutic strategy to counteract muscle atrophy in elderly and sedentary subjects."
   ]
  },
  "41421047": {
   "title": "An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity",
   "journal": "J Pharmacol Exp Ther",
   "year": "2026",
   "quotes": [
    "We previously developed an ERR pan-agonist, SLU-PP-332 (332), which improves aerobic performance in mice but lacks oral bioavailability.",
    "a chemically distinct ERR pan-agonist that is orally bioavailable"
   ]
  },
  "41850449": {
   "title": "Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling",
   "journal": "Int J Biol Macromol",
   "year": "2026",
   "quotes": [
    "SLU-PP-332 is a well-established exercise mimetic and widely used chemical probe for ERR activation"
   ]
  },
  "41588687": {
   "title": "In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential",
   "journal": "Rapid Commun Mass Spectrom",
   "year": "2026",
   "quotes": [
    "This capability prompted the consideration of these compounds as drugs potentially relevant for sports drug testing programs.",
    "human liver S9 fraction",
    "A total of nine metabolites were identified for SLU-PP-332",
    "This may help to uncover the illicit use of these novel compounds as potential performance-enhancing substances."
   ]
  },
  "41688415": {
   "title": "Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes",
   "journal": "Drug Test Anal",
   "year": "2026",
   "quotes": [
    "The World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics and metabolic modulators in sports.",
    "The identification of metabolites of this emerging therapeutic molecule is a critical step towards detecting its misuse.",
    "the 22 metabolites"
   ]
  },
  "42024694": {
   "title": "[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]",
   "journal": "Rev Med Chil",
   "year": "2026",
   "quotes": [
    "including experimental studies in animals and cell models",
    "SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.",
    "Clinical trials are needed to confirm their efficacy and safety in humans."
   ]
  },
  "41475667": {
   "title": "Estrogen-related receptor α in breast cancer: From molecular insights to targeted therapy",
   "journal": "Biochim Biophys Acta Rev Cancer",
   "year": "2026",
   "quotes": [
    "has emerged as a key regulator of tumor energy metabolism and a crucial driver of breast cancer progression"
   ]
  }
 },
 "full_text_quotes": {
  "pmc_11584170.txt": [
   "mice treated with the ERR agonist were able to run ∼70% longer and ∼45% further than vehicle-treated mice",
   "(n = 6 per group)",
   "we treated sedentary mice with SLU-PP-332 or vehicle for 7 days",
   "We observed no overt toxicity in mice administered SLU-PP-332",
   "which is consistent with the normal complete blood count and electrolyte levels",
   "the mERRα−/− treated with SLU-PP-332 displayed exercise endurance equivalent to vehicle-treated mERRα−/− mice",
   "intraperitoneal (i.p.) administration in mice",
   "T.P.B., B.E., and J.K.W. are stockholders in Myonid Therapeutics, Inc., which focuses on ERR based therapeutics."
  ],
  "pmc_10801787_page.txt": [
   "after 28 days of treatment the drug treated mice weighed ∼12% less",
   "vehicle-treated mice had gained ∼5 g of fat mass while drug-treated mice had gained less than 0.5 g of fat mass",
   "No difference in total body weight was observed after 28 days of treatment with SLU-PP-332",
   "Three weeks of SLU-PP-332 treatment did not affect glucose tolerance",
   "8 to 10 male C57BL6/J or ob/ob mice per group",
   "T.P.B., J.K.W., and B.E. are stockholders in Myonid Therapeutics, Inc. and Pelagos Pharmaceuticals, Inc."
  ],
  "pmc_10842599.txt": [
   "Lilei Zhang is the co-founder and consultant for Pelagos Pharmaceuticals Inc."
  ]
 },
 "competing_interest_statements": {
  "37421886": "John K. Walker has patent #WO2019036562; Heteroaromatics as ERR inverse agonists and their preparation licensed to Myonid Therapeutics.",
  "37717940": "None declared.",
  "41421047": "SLU-PP-915 is covered under the intellectual property of Saint Louis University, with Thomas P. Burris as an inventor. Thomas P. Burris is also a stockholder in Myonid Therapeutics, Inc, and Pelagos Pharmaceuticals, Inc, which are both active in developing ERR agonists.",
  "41850449": "B.E. and T.P.B. are cofounders and hold stock in Pelagos Pharmaceuticals, Inc.",
  "41588687": "The authors declare no conflicts of interest."
 },
 "press_releases": {
  "uf_news_2023_09_27": {
   "url": "https://news.ufl.edu/2023/09/exercise-mimicking-drug/",
   "quotes": [
    "The new treatment is in the early stages of development but could one day be tested in people",
    "So far, the drug hasn’t generated any severe side effects.",
    "The next step in developing SLU-PP-332 into a drug candidate will be to refine its structure, ideally making it available as a pill instead of an injection.",
    "Then the drug would be tested for side effects in more animal models before making the jump to human trials.",
    "This compound is basically telling skeletal muscle to make the same changes you see during endurance training"
   ]
  },
  "acs_2024_03_18": {
   "url": "https://www.acs.org/pressroom/presspacs/2024/march/mimicking-exercise-with-a-pill.html",
   "quotes": [
    "appear capable of mimicking the physical boost of working out — at least within rodent cells",
    "We cannot replace exercise; exercise is important on all levels",
    "While SLU-PP-332 cannot pass into the brain",
    "Elgendy and his colleagues hope to test the new compounds in animal models through Pelagos Pharmaceuticals, a startup company they have co-founded."
   ]
  }
 },
 "wada_2027": {
  "list_url": "https://www.wada-ama.org/sites/default/files/2026-09/2027list_en_final_clean_26_august_2026_2.pdf",
  "read_from": "FIS mirror of the identical file (wada-ama.org returned an empty 202 to the box)",
  "section": "S4.4.1 Metabolic modulators",
  "quotes": [
   "SLU-PP-332, SLU-PP-915 and related substances",
   "METABOLIC MODULATORS",
   "This List shall come into effect on 1 January 2027."
  ],
  "news_url": "https://www.wada-ama.org/en/news/wada-publishes-2027-prohibited-list",
  "news_published": "2026-09-21",
  "news_quote": "enters into force on 1 January 2027"
 },
 "usada": {
  "url": "https://www.usada.org/spirit-of-sport/athlete-advisory-2027-prohibited-list/",
  "quotes": [
   "SLU-PP-332 and SLU-PP-915 (metabolic modulators acting on oxidative metabolism)",
   "January 1, 2027"
  ]
 },
 "fda": {
  "drugsfda_matches": 0,
  "faers_reports": 0,
  "enforcement_reports": 0,
  "ndc_last_updated": "2026-10-23",
  "ndc_bulk_listings": {
   "total": 5,
   "distinct_labelers": 5,
   "by_category": {
    "BULK INGREDIENT": 3,
    "BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING": 2
   },
   "by_start_year": {
    "2025": 3,
    "2026": 2
   },
   "substance_field_matches_published_structure": 2,
   "substance_field_other": 3,
   "note": "Labelers counted, not named. A listing is a registration, not an FDA approval or quality finding, and says nothing about what any product contains."
  },
  "cats_503a_mentions": 0,
  "cats_503a_updated": "2026-05-14"
 },
 "clinicaltrials_gov": {
  "SLU-PP-332": 0,
  "SLU-PP-915": 0
 },
 "analysis": {
  "note": "Jabbit analysis. Every SLU-PP-332 result we found comes from mice or cells in a dish; no human has been given it in any published or registered trial. The headline endurance result came from 6 mice per group given injections; the developers later reported it lacks oral bioavailability and built an oral successor (SLU-PP-915). Developers disclose stock in companies working on ERR drugs. WADA bans it at all times from January 1, 2027."
 }
}